Bergmann, Karl-Christian http://orcid.org/0000-0002-0306-9922
Raab, Jennifer
Krause, Linda http://orcid.org/0000-0002-8490-5717
Becker, Sylvia
Kugler, Sebastian
Zuberbier, Torsten http://orcid.org/0000-0002-1466-8875
Roth-Walter, Franziska http://orcid.org/0000-0001-5005-9228
Jensen-Jarolim, Erika http://orcid.org/0000-0003-4019-5765
Kramer, Matthias F. http://orcid.org/0000-0002-3740-4733
Graessel, Anke http://orcid.org/0000-0001-9670-3269
Article History
Received: 18 November 2021
Accepted: 11 December 2021
First Online: 13 January 2022
Declarations
:
: K.-C. Bergmann reports personal fees for lectures: ALK, AstraZeneca, Allergopharma, Bencard, Chiesi, GSK, HAL, LETI, Lofarma, Mundipharma, Novartis, Sanofi. Non-financial support as Chair of German Pollen Information Service Foundation, personal fees and non-financial support from Consultant physician for ECARF, personal fees and non-financial support from Advisory Board member of AstraZeneca, ECARF, GSK, Robert-Koch-Institute Berlin (Vice chairman Public Health), Sanofi, outside the submitted work. J. Raab, M.F. Kramer, and A. Graessel are employees of Allergy Therapeutics/Bencard Allergie GmbH. S. Becker, L. Krause and S. Kugler declare that they have no competing interests. F. Roth-Walter received honoraria for presentations from Allergy Therapeutics and Bencard Allergie GmbH. E. Jensen-Jarolim and F. Roth-Walter are inventors on the immunoBON® patent (Patent EP 2 894 478 B1), owned by Biomedical International R + D, Vienna, Austria, of which EJJ E. Jensen-Jarolim is shareholder. E. Jensen-Jarolim received honoraria for presentations from Allergy Therapeutics, Allergopharma, Bencard, Meda, Roxall, ThermoFisher, and Vifor, and is consultant or in Advisory Boards for Allergy Therapeutics, Vifor Pharma, Sanofi, previously for MediGene, Germany, Novartis, and Dr. Schär (ceased). Prof. T. Zuberbier reports personal fees from Bayer Health Care, FAES, Novartis, Henkel, and AstraZeneca. He received fees for talks and personal fees from AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard Allergie GmbH, Berlin Chemie, HAL, Leti, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB Henkel, Kryolan, L’Oréal outside the submitted work.
: Study protocol was approved by the Ethics Committee of the Charité Berlin (EA1/412/20). All participants received detailed information from the supervising physician and provided their written informed consent to participate. Participants also agreed to the processing and storage of their data in accordance with the General Data Protection Regulation. Study was conducted in accordance with the Declaration of Helsinki and in compliance with all federal, regional and local requirements. All data provided were pseudonymised to protect the privacy of the study participants as mandated by the applicable laws and regulations.